

# Inhibition of Estradiol Uptake and Transforming Growth Factor $\alpha$ Secretion in Human Breast Cancer Cell Line MCF-7 by an Alkyl-lysophospholipid

Hiroshi Kosano,<sup>1</sup> Yosirou Yasutomo, Nobuo Kugai, Naokazu Nagata, Hirofumi Inagaki, Shigeaki Tanaka, and Osamu Takatani

Third Department of Internal Medicine, National Defense Medical College, 3-2, Namiki, Tokorozawa-shi, Saitama 359, Japan [H. K., Y. Y., N. K., N. N., O. T.], and Laboratory for Biochemistry, Pharma Research Laboratories, Hoechst Japan Limited [H. I., S. T.], Saitama 350, Japan

## ABSTRACT

We investigated the effect of 1-*O*-octadecyl-2-*O*-methyl-*sn*-glycero-3-phosphocholine (ET-18-OCH<sub>3</sub>), an alkyl-lysophospholipid, on the uptake of estrogen, the secretion of transforming growth factor (TGF)  $\alpha$  and the content of progesterone receptors (PRs) in the hormone-dependent breast cancer cell line, MCF-7. The uptake of labeled estradiol by MCF-7 was dose dependently decreased by 12 h pretreatment with 10–25  $\mu$ g/ml ET-18-OCH<sub>3</sub>, and this suppression occurred prior to the onset of the inhibitory action of ET-18-OCH<sub>3</sub> on MCF-7 growth. Scatchard analysis demonstrated that ET-18-OCH<sub>3</sub> reduced the number of estrogen receptors in MCF-7 without affecting their affinity. Both the secretion of TGF- $\alpha$  from MCF-7 into the conditioned medium and the PR content of MCF-7 were decreased by 48 h treatment with 10  $\mu$ g/ml ET-18-OCH<sub>3</sub>. The estradiol uptake, the TGF- $\alpha$  secretion, and the PR content were not affected by platelet-activating factor, lyso-PAF, and palmitoyl-lysophosphatidylcholine, all at 10  $\mu$ g/ml. These results suggest that the reduction of estrogen receptor level induced by ET-18-OCH<sub>3</sub> resulted in decreases in both the secretion of TGF- $\alpha$  and the content of PR in MCF-7, and these effects are specific to ET-18-OCH<sub>3</sub>.

We concluded that these effects of ET-18-OCH<sub>3</sub> may lead, at least partly, to its antitumor action in hormone-dependent breast cancer cell lines.

## INTRODUCTION

Breast cancer cells have been demonstrated to be associated with several autocrine growth factors (1, 2). It has also been reported that the proliferation of hormone-dependent breast cancer cells is controlled by autocrine growth factors such as TGF- $\alpha$ <sup>2</sup> (3), TGF- $\beta$  (4), and insulin-like growth factor type I (2, 5). One class of these factors, TGF- $\alpha$ , has been shown to act on breast cancer cells via an interaction with EGF receptors (6). Induction by estradiol of a TGF- $\alpha$ -like activity was reported in 3 species of hormone-sensitive breast cancer cells (3). Considerable research interests have been focused on the role of autocrine factors in the control of breast cancer cell proliferation.

Recently, we have reported that ET-18-OCH<sub>3</sub> inhibits the growth of MCF-7 and ZR-75-1, hormone-dependent breast cancer cell lines, by blocking EGF internalization and hence by reducing the EGF binding, while it does not affect both the growth of BT-20, a hormone-independent breast cancer cell line, and EGF binding to this cell line (7, 8).

In the present study, we investigated the effect of ET-18-OCH<sub>3</sub> on the estrogen uptake, TGF- $\alpha$  secretion, and PR content in the hormone-dependent breast cancer cell line, MCF-7.

Received 10/4/89; revised 1/29/90.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>1</sup> To whom requests for reprints should be addressed.

<sup>2</sup> The abbreviations used are: TGF, transforming growth factor; ET-18-OCH<sub>3</sub>, 1-*O*-octadecyl-2-*O*-methyl-*sn*-glycero-3-phosphocholine; EGF, epidermal growth factor; ER, estrogen receptor; PR, progesterone receptor; lyso-PAF, 1-*O*-octadecyl-2-hydroxy-*sn*-glycero-3-phosphocholine; PAF, 1-*O*-octadecyl-2-acetyl-*sn*-glycero-3-phosphocholine (platelet activating factor); LPC, palmitoyllysophosphatidylcholine; TPA, phorbol-12-tetradecanoate-13-acetate; FBS, fetal bovine serum; DCC, dextran-coated charcoal; EIA, enzyme immunoassay; PBS, phosphate-buffered saline; PKC, protein kinase C.

## MATERIALS AND METHODS

**Chemicals.** [<sup>3</sup>H]Estradiol (166 Ci/mmol) was purchased from New England Nuclear (Boston, MA). ET-18-OCH<sub>3</sub>, lyso-PAF, and PAF were obtained from BACHEM Feinchemikalien AG (Bubendorf, Switzerland), and LPC (from egg yolk) was from Sigma Chemical Co. (St. Louis, MO). All other chemicals used were purchased from Wako Pure Chemical Industries (Osaka, Japan).

**Cell Lines.** The human breast cancer cell line, MCF-7, was subcultured in RPMI 1640 (Flow Laboratories, McLean, VA) supplemented with 10% (v/v) FBS (Filtron, Altona, Australia) as described previously (7). For experiments involving estrogen induction, the cells were passaged for at least 1 week in RPMI 1640 supplemented with 10% FBS treated with DCC (9) and contained 10 nM estradiol with a final 0.1% of absolute ethanol in order to keep the estrogenic action constant.

**Collection of Conditioned Media.** MCF-7 cells were cultured for 3 days to a density of 4–6  $\times$  10<sup>6</sup> cells/flask in the growth medium, RPMI 1640, supplemented with 10% DCC-FBS containing 10 nM estradiol in T-150 flasks (Falcon No. 3024; Becton-Dickinson, Lincoln Park, NJ). The growth medium was removed, and the cells were rinsed twice with RPMI 1640 and then incubated for 48 h in RPMI 1640 containing ET-18-OCH<sub>3</sub> or one of its analogues, LPC, lyso-PAF, and PAF. [The stock solution (0.5 mg/ml) of ET-18-OCH<sub>3</sub> or each of the analogues was added to RPMI 1640 to obtain desired concentrations.] The medium was harvested and centrifuged at 3500 rpm for 10 min, the supernatant was dialyzed for 2 days in a SpectraPor 3 membrane (*M*, 3500 cutoff) (Fisher Scientific, Los Angeles, CA) against distilled water. Finally, the dialysate was lyophilized, and the obtained powder was dissolved in 0.1 volume of distilled water.

**Preparation of Cytosols.** All the following procedures were carried out at 0–4°C unless otherwise specified. After collection of conditioned media, monolayer cells were harvested with 0.25% trypsin/0.5% EDTA solution for PR assays using an EIA kit. The cells were washed twice with PBS and added to the homogenization buffer (10 mM Tris-1 mM EDTA-3 mM Na<sub>2</sub>S<sub>2</sub>O<sub>4</sub>-12 mM thioglycerol-10% glycerol, pH 7.4) to be 5  $\times$  10<sup>6</sup> cells/ml. This cell suspension was gently homogenized by a Potter-type homogenizer, and the homogenate was centrifuged at 800  $\times$  g for 10 min. The supernatant was removed and saved, and the pellet was resuspended in 5 volumes of the homogenization buffer. After centrifugation at 800  $\times$  g for 10 min, the supernatant was collected and combined with the former supernatant, and the total supernatant was centrifuged at 105,000  $\times$  g for 1 h. The resultant supernatant was obtained as the cytosol.

**Uptake of [<sup>3</sup>H]Estradiol by Breast Cancer Cell Line MCF-7.** Measurement of [<sup>3</sup>H]estradiol uptake and Scatchard analysis were carried out as described previously (10). MCF-7 cells were plated to be 1  $\times$  10<sup>5</sup> cells/well in a 12-well culture dish (No. 3512; Coster, Cambridge, MA) and cultured for 3 days in the RPMI 1640 containing 10% DCC-FBS. ET-18-OCH<sub>3</sub> was then added and cultured for 12 h, and the medium was removed and replaced with 0.5 ml RPMI 1640 containing 0.1% bovine serum albumin and 6 nM [<sup>3</sup>H]estradiol with or without 100-fold molar excess of unlabeled estradiol. The cells were incubated at 37°C for 1 h after the addition of the radiolabeled compound. The medium was removed and replaced with 1.0 ml of the PBS containing 0.5% bovine serum albumin (5 mM sodium phosphate-0.25 M sucrose-10% glycerol, pH 7.4), and the cells were allowed to stand for 30 min at room temperature. The cells were then rinsed twice each with 1.0 ml cold PBS, and 1 ml ethanol was added to each well. After 30 min incubation at room temperature, the ethanol was transferred to a scintillation vial, and the <sup>3</sup>H radioactivity in the ethanol was counted

in a liquid scintillation counter (LSC-3500; Aloka, Tokyo, Japan).

**Enzyme Immunoassay of PR.** The EIA kit for PR was purchased from Dainabot Laboratories (Tokyo, Japan). All procedures for PR-EIA were carried out according to the method described previously by Noguchi *et al.* (11). The intraassay coefficient of variation of this assay was <5.2%.

**Enzyme Immunoassay of TGF- $\alpha$ .** TGF- $\alpha$  was measured by the sandwich type enzyme-linked immunosorbent with rabbit antibody (affinity purified) and mouse monoclonal antibody ATG-2S as described by Inagaki *et al.* (12).

**Growth Experiment.** Cell proliferation was monitored at various stages by measuring DNA as described previously (7). Total protein was measured by the method of Lowry *et al.* (13).

## RESULTS

As shown in Fig. 1, the uptake of [ $^3$ H]estradiol by MCF-7 was dose dependently decreased by 12 h pretreatment with 10–25  $\mu$ g/ml of ET-18-OCH $_3$ .

Fig. 2 shows the relation between the time of pretreatment with 10  $\mu$ g/ml ET-18-OCH $_3$  and the uptake of labeled estradiol by MCF-7. The specific uptake of labeled estradiol was decreased significantly ( $P < 0.05$ ) by 12 h pretreatment with ET-18-OCH $_3$  and further decreased to 61.5  $\pm$  7.3% (SD) ( $n = 3$ )




Fig. 1. Dose dependence of the inhibitory effect of ET-18-OCH $_3$  pretreatment on the specific uptake of [ $^3$ H]estradiol by human breast cancer cell line MCF-7. The cells were preincubated for 12 h in the presence of 3–25  $\mu$ g/ml ET-18-OCH $_3$ . The values plotted are the mean  $\pm$  SD (bars) of triplicate determinations in one typical experiment and normalized to the control (352.0  $\pm$  23.0 cpm/ $\mu$ g DNA as 100%) measured in the absence of ET-18-OCH $_3$ . The level of significance as compared to the control (Student's  $t$  test): \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ .




Fig. 2. Time dependence of the inhibitory effect of ET-18-OCH $_3$  pretreatment on the specific uptake of [ $^3$ H]estradiol by MCF-7. The cells were pretreated for 3–48 h at 37°C with 10  $\mu$ g/ml ET-18-OCH $_3$ . After washing, the specific uptake of [ $^3$ H]estradiol was measured by whole cell uptake method (10). The values plotted are the mean  $\pm$  SD (bars) of triplicate determinations in one typical experiment and normalized to the control (334.0  $\pm$  8.9 cpm/ $\mu$ g DNA as 100%) measured in the absence of ET-18-OCH $_3$ . The level of significance as compared to the control (Student's  $t$  test): \*,  $P < 0.05$ ; \*\*,  $P < 0.001$ .

of control at 24 h ( $P < 0.001$ ) and to 62.4  $\pm$  7.6% ( $n = 3$ ) at 48 h ( $P < 0.001$ ).

The results of Scatchard analysis of the specific uptake of labeled estradiol by MCF-7 are shown in Fig. 3. By treatment with 10  $\mu$ g/ml ET-18-OCH $_3$  for 12 h, the maximum uptake of labeled estradiol was decreased from 7.4 fmol/ $\mu$ g DNA ( $6.1 \times 10^4$  sites/cell) to 4.8 fmol/ $\mu$ g DNA ( $4.0 \times 10^4$  sites/cell), while the uptake rate was unaltered (0.44 nM for control and 0.45 nM in the presence of 10  $\mu$ g/ml ET-18-OCH $_3$ ).

The effects of pretreatment with ET-18-OCH $_3$  and its analogues on the uptake of labeled estradiol by MCF-7 are shown in Table 1. The uptake of [ $^3$ H]estradiol by MCF-7 was significantly ( $P < 0.05$ ) decreased by 12 h pretreatment of MCF-7 with 10  $\mu$ g/ml ET-18-OCH $_3$ , while no such decrease was observed after 12 h pretreatment with 10  $\mu$ g/ml of any one of LPC, lyso-PAF, and PAF.

The effects of pretreatment with ET-18-OCH $_3$  and its analogues on the amount of TGF- $\alpha$  secreted from MCF-7 into the conditioned medium and on the content of PR in MCF-7 are shown in Table 2. The secretion of TGF- $\alpha$  from MCF-7 was significantly ( $P < 0.01$ ) suppressed by 48 h pretreatment with 10  $\mu$ g/ml ET-18-OCH $_3$ , namely from 4.29  $\pm$  0.07 ng/ $10^7$  cells to 2.77  $\pm$  0.50 ng/ $10^7$  cells or from 1.43  $\pm$  0.02 ng/mg total




Fig. 3. Scatchard analysis of the specific uptake of [ $^3$ H]estradiol by MCF-7 incubated in the presence and absence of ET-18-OCH $_3$ . The cells were pretreated for 12 h at 37°C with (●) or without (○) 10  $\mu$ g/ml ET-18-OCH $_3$ . The data shown are the mean of triplicate determinations.

Table 1 Effects of ET-18-OCH $_3$  and its analogues on the uptake of [ $^3$ H]estradiol by MCF-7

Drug (10 $\mu$ g/ml)	[ $^3$ H]Estradiol uptake	
	cpm/ $\mu$ g DNA	% of control
Control	349.2 $\pm$ 16.6 <sup>a</sup>	100
LPC	365.0 $\pm$ 24.0	105
Lyso-PAF	339.6 $\pm$ 18.6	97
PAF	356.3 $\pm$ 20.8	102
ET-18-OCH $_3$	275.2 $\pm$ 25.8 <sup>b</sup>	79

<sup>a</sup> Mean  $\pm$  SD of triplicate determinations.

<sup>b</sup>  $P < 0.05$  compared to the control value (Student's  $t$  test).

Table 2 Amount of TGF- $\alpha$  secreted from MCF-7 into the conditioned medium and progesterone receptor content of MCF-7 cultured for 48 h with 10  $\mu$ g/ml ET-18-OCH $_3$  and its analogues

Drug	TGF- $\alpha$		Progesterone receptor	
	ng/ $10^7$ cells	% of control	fmol/ $10^6$ cells	% of control
Control	4.29 $\pm$ 0.07 <sup>a</sup>	100	74.5 $\pm$ 4.3	100
LPC	4.55 $\pm$ 0.22	106	78.2 $\pm$ 7.6	105
Lyso-PAF	4.24 $\pm$ 0.39	99	74.8 $\pm$ 2.7	100
PAF	4.09 $\pm$ 0.53	95	70.2 $\pm$ 5.1	94
ET-18-OCH $_3$	2.77 $\pm$ 0.50 <sup>b</sup>	65	55.8 $\pm$ 5.1 <sup>c</sup>	75

<sup>a</sup> Mean  $\pm$  SD of triplicate observations.

<sup>b</sup>  $P < 0.01$  compared to the control value (Student's  $t$  test).

<sup>c</sup>  $P < 0.05$  compared to the control value (Student's  $t$  test).

protein to  $0.83 \pm 0.15$  ng/mg total protein (58% of control), the total protein being 3.0 mg/10<sup>7</sup> cells and 3.3 mg/10<sup>7</sup> cells for control and 10  $\mu$ g/ml ET-18-OCH<sub>3</sub>-treated MCF-7 cells, respectively. On the other hand, pretreatment for 48 h with 10  $\mu$ g/ml of LPC, lyso-PAF, or PAF showed no significant effect on the secretion of TGF- $\alpha$ . Similarly, the PR content of MCF-7 was also significantly ( $P < 0.05$ ) decreased by 48 h pretreatment with 10  $\mu$ g/ml ET-18-OCH<sub>3</sub>, while no such effect was noted after 48 h pretreatment with 10  $\mu$ g/ml of LPC, lyso-PAF, or PAF.

## DISCUSSION

We have reported previously that ET-18-OCH<sub>3</sub> inhibits the growth of hormone-dependent breast cancer cell lines, MCF-7 and ZR-75-1, by blocking EGF internalization and hence by reducing the EGF binding, while it does not affect both the growth of and the EGF binding to the hormone-independent breast cancer cell line, BT-20 (7, 8). In the present study, we further investigated the effect of ET-18-OCH<sub>3</sub> on the uptake of labeled estradiol, the secretion of TGF- $\alpha$  in conditioned medium, and the PR content in the hormone-dependent breast cancer cell line, MCF-7.

Since the ER is generally said to be located inside the cell, cytoplasm, and/or nucleus (14), the uptake of labeled estradiol measured here is assumed to represent the binding of labeled estradiol to ERs in the following discussion.

It was found in the present study that the uptake of labeled estradiol by MCF-7 was significantly ( $P < 0.05$ ) reduced, when the cells were preincubated with more than 10  $\mu$ g/ml ET-18-OCH<sub>3</sub> for 12 h or longer. In 12 h preincubation, 10  $\mu$ g/ml ET-18-OCH<sub>3</sub> halved the maximum binding of labeled EGF to MCF-7 in the previous study (7) and significantly decreased the uptake of labeled E<sub>2</sub> by MCF-7 in the present study. Further, the growth of MCF-7 was little affected by preincubation with 10  $\mu$ g/ml ET-18-OCH<sub>3</sub> for 12 h monitored by DNA content and [<sup>3</sup>H]thymidine uptake (7). Therefore, we used here an incubation time of 12 h and an ET-18-OCH<sub>3</sub> concentration of 10  $\mu$ g/ml.

Scatchard plots showed that ET-18-OCH<sub>3</sub> caused an apparent reduction in the maximum binding of labeled estradiol without affecting the binding affinity. It has been reported recently by Murphy *et al.* (15) that the <sup>125</sup>I-EGF binding is not induced by estradiol, and this provides strong evidence that estradiol is not involved in the steroidal regulation of the expression of EGF receptors in hormone-dependent breast cancer cell lines. On the other hand, Berthois *et al.* (16) have found that a short-term (24–48 h) treatment of MCF-7 with estradiol leads to a decrease in the number of EGF receptors. Moreover, Cormier *et al.* (17) have demonstrated that the treatment of MCF-7 with EGF can inhibit estradiol-stimulated PR synthesis, and EGF appears to down-regulate the ER by approximately 50% in MCF-7.

Based on these previous studies (15–17) of the relationship between the EGF receptor and estradiol and also on the data shown here in Figs. 1–3, we tentatively speculate at present that ET-18-OCH<sub>3</sub> might directly decrease the number of ERs, and this effect is specific to ET-18-OCH<sub>3</sub>. How ET-18-OCH<sub>3</sub> decreases the number of ERs in MCF-7 is unclear at present and must be a subject for future studies.

TGF- $\alpha$ , which is induced by estradiol, may be one of important regulators in hormone-dependent breast cancer cell lines (1, 2). Moreover, PRs are said to be induced by the effect of estradiol on ERs (18). Therefore, both TGF- $\alpha$  and PR are

regulated by the effect of estradiol on ERs. In our findings, the secretion of TGF- $\alpha$  from MCF-7 into the conditioned medium was inhibited and the PR content of MCF-7 was decreased by 48 h pretreatment with 10  $\mu$ g/ml ET-18-OCH<sub>3</sub>, while LPC, lyso-PAF, and PAF, all at 10  $\mu$ g/ml, did not affect both the TGF- $\alpha$  secretion and the PR content. It is conceivable from these findings that the reduction in ER level induced by ET-18-OCH<sub>3</sub> resulted in decreases in the secretion of TGF- $\alpha$  from MCF-7 and the PR content of this cell line. It is likely that the suppression of TGF- $\alpha$  precedes the inhibition of cell growth induced by 10  $\mu$ g/ml ET-18-OCH<sub>3</sub>, because the growth of MCF-7 was little affected by pretreatment with 10  $\mu$ g/ml ET-18-OCH<sub>3</sub> for 12 h (7) and also because that a significant reduction in ER occurred only after MCF-7 was treated with ET-18-OCH<sub>3</sub> for more than 12 h.

Recently, Roos *et al.* (19) have preliminarily demonstrated that TPA decreases not only the EGF binding but also the level of PR, but not that of ER, in hormone-dependent breast cancer cells. ET-18-OCH<sub>3</sub>, on the other hand, reduced both the uptake of labeled estradiol and the PR content in MCF-7 as reported here and also decreased the EGF binding to MCF-7 and ZR-75-1 as reported previously (7). These findings indicate a difference in the mode of action between ET-18-OCH<sub>3</sub> and TPA.

According to the report of Ghosh-Dastidar *et al.* (20), PR is a high affinity substrate for phosphorylation by the EGF receptor kinase, and the level of PRs is said to be controlled by TPA through this phosphorylation. The down-regulation of the EGF receptor mediated by PKC may also change the state of phosphorylation of PRs, resulting in a final reduction in the receptor concentration (19). TPA is a PKC activator (21), while ET-18-OCH<sub>3</sub> is a PKC inhibitor (22). This functional difference may account for the difference in the mode of steroid receptor regulation between TPA and ET-18-OCH<sub>3</sub>, although further investigation are required on this point.

From these results together with our previous findings (7, 8), we conclude that ET-18-OCH<sub>3</sub> reduces not only the EGF binding probably by inhibiting EGF internalization but also the secretion of TGF- $\alpha$  by reducing ER sites. These effects of ET-18-OCH<sub>3</sub> may lead to its antitumor action in hormone-dependent breast cancer cell lines. If this concept could be extended to hormone-dependent breast cancers in general, the modulation of EGF binding and the inhibition of TGF- $\alpha$  secretion by ET-18-OCH<sub>3</sub> may become useful probes for treatment of breast cancer.

## ACKNOWLEDGMENTS

We thank Dr. K. Okamoto, Department of Pharmacology, National Defense Medical College, for helpful comments.

## REFERENCES

- Lippman, M. E., Dickson, R. B., Kasid, A., Gelmann, E., Davidson, N., McManaway, M., Huff, K., Bronzert, D., Bates, S., Swain, S., and Knabbe, C. Autocrine and paracrine growth regulation of human breast cancer. *J. Steroid Biochem.*, **24**: 147–154, 1986.
- Dickson, R. B., and Lippman, M. E. Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. *Endocr. Rev.*, **8**: 29–43, 1987.
- Dickson, R. B., Bates, S. E., McManaway, M. E., and Lippman, M. E. Characterization of estrogen responsive transforming activity in human breast cancer cell lines. *Cancer Res.*, **46**: 1707–1713, 1986.
- Knabbe, C., Lippman, M. E., Wakefield, L. M., Flanders, K. C., Kasid, A., Derynck, R., and Dickson, R. B. Evidence that transforming growth factor- $\beta$  is a hormonally regulated negative growth factor in human breast cancer cells. *Cell*, **48**: 417–428, 1987.
- Huff, K. K., Kaufman, D., Gabbay, K. H., Spencer, E. M., Lippman, M. E., and Dickson, R. B. Secretion of an insulin-like growth factor-I-related protein by human breast cancer cells. *Cancer Res.*, **46**: 4613–4619, 1986.

6. Pike, L. J., Marquardt, H., Todaro, G. J., Gallis, B., Casnellie, J. E., Bornstein, P., and Krebs, E. G. Transforming growth factor and epidermal growth factor stimulate the phosphorylation of a synthetic, tyrosine-containing peptide in a similar manner. *J. Biol. Chem.*, *257*: 14628-14631, 1982.
7. Kosano, H., and Takatani, O. Reduction of epidermal growth factor binding in human breast cancer cell lines by an alkyl-lysophospholipid. *Cancer Res.*, *48*: 6033-6036, 1988.
8. Kosano, H., and Takatani, O. Inhibition by an alkyl-lysophospholipid of the uptake of epidermal growth factor (EGF) in human breast cancer cell lines in relation to EGF internalization. *Cancer Res.*, *49*: 2868-2870, 1989.
9. Horwitz, K. B., and McGuire, W. L. Nuclear mechanisms of estrogen action: effects of estradiol and antiestrogens on estrogen receptor and nuclear receptor processing. *J. Biol. Chem.*, *253*: 8185-8198, 1978.
10. Taylor, C. M., Blanchard, B., and Zava, D. T. A simple method to determine whole cell uptake of radiolabelled oestrogen and progesterone and their subcellular localization in breast cancer cell lines in monolayer culture. *J. Steroid Biochem.*, *20*: 1083-1088, 1984.
11. Noguchi, S., Miyauchi, K., Imaoka, S., Koyama, H., and Iwanaga, T. Comparison of enzyme immunoassay with dextran-coated charcoal method in the determination of progesterone receptor in breast cancer cytosols. *Eur. J. Cancer Clin. Oncol.*, *24*: 1715-1719, 1988.
12. Inagaki, H., Katoh, M., Kurosawa-Ohsawa, K., and Tanaka, S. A new sandwich enzyme-linked immunosorbent assay (ELISA) for transforming growth factor  $\alpha$  (TGF  $\alpha$ ) based upon conformational modification by antibody binding. *J. Immunol. Methods*, in press, 1990.
13. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. Protein measurement with the Folin phenol reagent. *J. Biol. Chem.*, *193*: 265-275, 1951.
14. Jensen, E. V., and DeSombre, E. R. Estrogen-receptor interaction; estrogenic hormones effect transformation of specific receptor proteins to a biochemically functional form. *Science (Wash. DC)*, *182*: 126-134, 1973.
15. Murphy, L. J., Sutherland, R. L., Stead, B., Murphy, L. C., and Lazarus, L. Progesterone regulation of epidermal growth factor receptor in human mammary carcinoma cells. *Cancer Res.*, *46*: 728-734, 1986.
16. Berthois, Y., Dong, X. F., and Martin, P. M. Regulation of epidermal growth factor-receptor by estrogen and antiestrogen in the human breast cancer cell line MCF-7. *Biochem. Biophys. Res. Commun.*, *159*: 126-131, 1989.
17. Cormier, E. M., Wolf, M. F., and Jordan, V. C. Decrease in estradiol-stimulated progesterone receptor production in MCF-7 cells by epidermal growth factor and possible clinical implication for paracrine-regulated breast cancer growth. *Cancer Res.*, *49*: 576-580, 1989.
18. Horwitz, K. B., and McGuire, W. L. Estrogen control of progesterone receptor in human breast cancer: correlation with nuclear processing of estrogen receptor. *J. Biol. Chem.*, *253*: 2223-2228, 1978.
19. Roos, W., Fabbro, D., Kung, W., Costa, S. D., and Eppenberger, U. Correlation between hormone dependency and the regulation of epidermal growth factor receptor by tumor promoters in human mammary carcinoma cells. *Proc. Natl. Acad. Sci. USA*, *83*: 991-995, 1986.
20. Ghosh-Dastidar, P., Coty, W. A., Griest, R. E., Woo, D. D. L., and Fox, C. F. Progesterone receptor subunits are high-affinity substrates for phosphorylation by epidermal growth factor receptor. *Proc. Natl. Acad. Sci. USA*, *81*: 1654-1658, 1984.
21. Castagna, M., Takai, Y., Kaibuchi, K., Sano, K., Kikkawa, U., and Nishizuka, Y. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. *J. Biol. Chem.*, *257*: 7847-7851, 1982.
22. Daniel, L. W., Small, G. W., and Schmitt, J. D. Alkyl-linked diglycerides inhibit protein kinase C activation by diacylglycerols. *Biochem. Biophys. Res. Commun.*, *151*: 291-297, 1988.

# Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

## Inhibition of Estradiol Uptake and Transforming Growth Factor $\alpha$ Secretion in Human Breast Cancer Cell Line MCF-7 by an Alkyl-lysophospholipid

Hiroshi Kosano, Yosirou Yasutomo, Nobuo Kugai, et al.

*Cancer Res* 1990;50:3172-3175.

**Updated version** Access the most recent version of this article at:  
<http://cancerres.aacrjournals.org/content/50/11/3172>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://cancerres.aacrjournals.org/content/50/11/3172>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.